![\"LOGO\"\/](\"https:\/\/www.europesays.com\/france\/wp-content\/uploads\/2026\/06\/g118903logo2.jpg\")
\n<\/p>\n\u00a0<\/p>\n
About\u00a0Sanofi <\/p>\n
Sanofi is an R&D driven, AI-powered biopharma company
\ncommitted to improving people\u2019s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative
\npipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people\u2019s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we
\nserve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY <\/p>\n
Media Relations <\/p>\n
Sandrine\u00a0Guendoul\u00a0| +33 6 25 09 14 25 |\u00a0sandrine.guendoul@sanofi.com <\/p>\n
Evan\u00a0Berland\u00a0| +1 215 432 0234 |\u00a0evan.berland@sanofi.com <\/p>\n
L\u00e9o Le Bourhis\u00a0| +33 6 75 06 43 81
\n|\u00a0leo.lebourhis@sanofi.com <\/p>\n
L\u00e9a Ubaldi\u00a0| +33 6 30 19 66 46 |\u2009lea.ubaldi@sanofi.com <\/p>\n
Laura Romby\u00a0| +33 6 74 16 74 29
\n|\u00a0laura.romby@sanofi.com <\/p>\n
Ekaterina
\nPesheva\u00a0| +1 410 926 6780 |\u00a0ekaterina.pescheva@sanofi.com <\/p>\n
Victor Rouault\u00a0| +1 617 356 4751 |\u00a0victor.rouault@sanofi.com <\/p>\n
Timothy Gilbert\u00a0| +1 516 521 2929
\n|\u00a0timothy.gilbert@sanofi.com <\/p>\n
Investor Relations <\/p>\n
Thomas Kudsk Larsen\u00a0|+ 44 7545 513 693 |\u00a0thomas.larsen@sanofi.com <\/p>\n
Aliz\u00e9
\nKaisserian\u00a0| + 33 6 47 04 12 11 |\u00a0alize.kaisserian@sanofi.com <\/p>\n
Keita Browne\u00a0| + 1 781 249 1766 |\u00a0keita.browne@sanofi.com <\/p>\n
Nathalie Pham\u00a0| + 33 7 85 93 30 17
\n|\u00a0nathalie.pham@sanofi.com <\/p>\n
Nina
\nGoworek\u00a0| +1 908 569 7086 |\u00a0nina.goworek@sanofi.com <\/p>\n
Thibaud Ch\u00e2telet\u00a0| + 33 6 80 80 89 90
\n|\u00a0thibaud.chatelet@sanofi.com <\/p>\n
Yun
\nLi\u00a0| +33 6 84 00 90 72 |\u00a0yun.li3@sanofi.com <\/p>\n
Sanofi Forward-Looking Statements <\/p>\n
This press
\nrelease contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These
\nstatements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and
\npotential, and statements regarding future events and economic performance. Words such as \u201cexpect,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cintend,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201ccan,\u201d
\n\u201ccontemplate,\u201d \u201ccould,\u201d \u201cis designed to,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cpotential,\u201d \u201cobjective,\u201d \u201cattempt,\u201d \u201ctarget,\u201d \u201cproject,\u201d
\n\u201cstrategy,\u201d \u201cstrive,\u201d \u201cdesire,\u201d \u201cpredict,\u201d \u201cforecast,\u201d \u201cambition,\u201d \u201cguideline,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cgoal,\u201d or
\nthe negative of these, and similar expressions are intended to identify forward-looking statements. Although Sanofi\u2019s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are
\ncautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ
\nmaterially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data
\nand analysis, including post marketing, decisions by regulatory authorities, such as the U.S Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application that may be
\nfiled for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates; the fact that product candidates if approved may not be
\ncommercially successful; unexpected regulatory actions or delays, or government regulation generally; authorities\u2019 decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower
\ndrug prices including \u201cmost favored nation\u201d pricing for State Medicaid programs; the future approval and commercial success of therapeutic alternatives; Sanofi\u2019s ability to benefit from external growth opportunities, to complete
\nrelated transactions and\/or obtain regulatory clearances, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in
\ngeneral; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation;\u00a0trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost
\ncontainment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and
\non the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under \u201cRisk
\nFactors\u201d and \u201cCautionary Statement Regarding Forward-Looking Statements\u201d in Sanofi\u2019s annual report on Form 20-F for the year ended December\u00a031, 2025 or contained in our periodic
\nreports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties
\nand assumptions, you should not place undue reliance on any forward-looking statements contained herein. <\/p>\n
\u00a0<\/p>\n
\n
\n<\/p>\n
\u00a0\u00a0
\n2\/2<\/p>\n","protected":false},"excerpt":{"rendered":"\u00a0 About\u00a0Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people\u2019s lives and delivering compelling…\n","protected":false},"author":2,"featured_media":40607,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12983],"tags":[27355,16844,27935,17059,23434,27936,27937,13012,14259,22208,24696],"class_list":["post-40606","post","type-post","status-publish","format-standard","has-post-thumbnail","category-sanofi","tag-cenrifki","tag-drug-approvals","tag-form-6-k","tag-immune-thrombocytopenia","tag-multiple-myeloma","tag-multiple-sclerosis","tag-paulo-fontoura","tag-sanofi","tag-sarclisa","tag-sny","tag-wayrilz"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts\/40606","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/comments?post=40606"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts\/40606\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/media\/40607"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/media?parent=40606"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/categories?post=40606"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/tags?post=40606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}